EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 948 participants.
Also called NCT03950076
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 948 participants
- Registry
-
NCT03950076
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Argentina, Austria, Belgium, Canada, China, Czechia, Egypt, Germany, India, Nepal, Portugal, Spain, Switzerland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03950076. Randomized; single masking; primary purpose prevention. Start 2019-09-20 (actual); primary completion 2026-07-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
- Acronym
- ENRICH-AF
- Condition
- Intracranial Hemorrhages
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Edoxaban
- Intervention (Other)
- Non-anticoagulant medical therapy
- Lead sponsor
- Population Health Research Institute
Record details
- Record id
cardio:ct-nct03950076- Content hash
abc5355a8e2b6472f4a127d71542dfe944126cb087741eb422ad52d550146cc0